Format

Send to

Choose Destination
Int J Mol Med. 1999 May;3(5):537-44.

Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review).

Author information

1
Department of Immunology, Institute of Biostructure, Medical University of Warsaw, 02-004 Warsaw, Poland.

Abstract

Interleukin-12 (IL-12) previously called cytotoxic lymphocyte maturation factor (CLMF) or NK cell stimulatory factor (NKSF) is a recently characterized heterodimeric cytokine composed of two subunits. Although identified no more than 10 years ago IL-12 has already proved efficacious in numerous pre-clinical tumor immunotherapy studies. Animal studies revealed that IL-12 has powerful antitumor, anti-metastatic and anti-angiogenic activities and seems to be less toxic than other immunotherapeutics such as interferons or IL-2. A number of pre-clinical studies with IL-12 prompted the evaluation of this cytokine in the treatment of human cancers. Results of phase I and early phase II clinical trials have already been reported and these are described here together with a brief discussion concerning IL-12-related toxicities and potential methods of their prevention.

PMID:
10202188
DOI:
10.3892/ijmm.3.5.537
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Spandidos Publications
Loading ...
Support Center